Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis.
about
Antiplatelet resistance in strokeHigh-maintenance-dose clopidogrel in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysisCriticial limb ischemia: epidemiologyMean platelet volume: a potential biomarker of the risk and prognosis of heart diseaseImpact of aspirin and clopidogrel interruption on platelet function in patients undergoing major vascular surgeryIndividualization of treatments with drugs metabolized by CES1: combining genetics and metabolomics.Variable effect of P2Y12 inhibition on platelet thrombus volume in flowing blood.Clopidogrel: the data, the experience, and the controversies.Projected inhibition of platelet aggregation with ticagrelor twice daily vs. clopidogrel once daily based on patient adherence data (the TWICE project).Low platelet disaggregation predicts poor response to 150 mg clopidogrel in patients with elevated platelet reactivity.Comparison of conventional aggregometry with VASP for monitoring P2Y12-specific platelet inhibition.P2Y12 platelet receptors: importance in percutaneous coronary interventionGenetic testing for CYP450 polymorphisms to predict response to clopidogrel: current evidence and test availability. Application: pharmacogenomics.Novel antiplatelet agents in the prevention of cardiovascular complications--focus on ticagrelor.Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis.Use of the pipeline embolization device to treat recently ruptured dissecting cerebral aneurysmsParaoxonase-1 is not a major determinant of stent thrombosis in a Taiwanese populationQuality of systematic reviews of observational nontherapeutic studies.Clinical importance of aspirin and clopidogrel resistanceDual antiplatelet therapy in secondary prevention of ischemic stroke: a ghost from the past or a new frontier?Efficacy and safety of individually tailored antiplatelet therapy in patients with acute coronary syndrome after coronary stenting: a single center, randomized, feasibility study.Tailored antiplatelet therapy and clinical adverse outcomes.Detection of clopidogrel hyporesponsiveness using a point-of-care assay and the impact of additional cilostazol administration after coronary stent implantation in diabetic patients.Monitoring the effectiveness of antiplatelet therapy: opportunities and limitations.Personalised medicine: not just in our genes.Prevalence and risk factors of clopidogrel non-response among Saudi patients undergoing coronary angiographyCurrent concepts about inhibition of platelet aggregation.Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the WoThe potential role of prasugrel in secondary prevention of ischemic events in patients with acute coronary syndromes.CYP2C19*2/ABCB1-C3435T polymorphism and risk of cardiovascular events in coronary artery disease patients on clopidogrel: is clinical testing helpful?Update on oral antiplatelet therapy: principles, problems and promises.A clinician's perspective of emerging P2Y(12)-directed pharmacotherapies, ex vivo measurement tools, and clinical outcomes.Platelet P2Y12 receptor inhibition by thienopyridines: status and future.Effect of pharmaceutical interventions targeting thromboxane receptors and thromboxane synthase in cardiovascular and renal diseases.Comparison of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention.Relation of CYP2C19 loss-of-function polymorphism to the occurrence of stent thrombosis.Benefits of and safety concerns associated with drug-eluting coronary stents.Thrombin receptor antagonism -the potential of antiplatelet medication SCH 530348.Aspirin and clopidogrel resistance: methodological challenges and opportunities.Point-of-care testing for assessment of adequacy of oral antiplatelet therapy in patients with cardiovascular disease.
P2860
Q22305927-F7058687-EDD1-4BE3-B2B5-72C0AF71C863Q26996325-E9290F3F-3909-41F1-80C2-1E39FF236F56Q27026881-4C91F5E9-3679-42E3-AE43-8BD3FF9C28AAQ28076282-6A9EFD10-639E-4605-91FD-3515390C6B46Q28542407-306E0164-3959-4B95-8653-FA1C95DE2DA3Q30373969-A21928B9-3F69-478C-BA26-89B5008E8714Q30498026-B44ECE28-172B-437C-BE85-30B63779154CQ30573045-D51B4021-C12F-43B3-9B38-A39ADCA05483Q30827217-D62459A3-C1B5-4081-9D51-83195EF1123FQ33516375-68C3D89F-7493-40AE-890A-4702C188F75CQ33636020-9FEF4A8C-56F4-46D6-B45D-1615D7A05CA7Q33655109-3D019F3A-BA60-4F49-A9FF-0334DA6388FCQ33704998-53F336F8-00CE-4B3C-A5B7-00ABB0B52AA0Q33902628-A6B9C6E6-3DA3-4FEC-9335-0456D0DE6C77Q33982372-38FD61FF-775E-4620-8CD3-D85B983C67F6Q34296893-DA50947D-87E1-42F2-A359-EFF117276D0AQ34314265-DE8FC1C8-AA3D-4C27-A0A6-925FB84507C2Q34371293-2C08D777-2ACB-41E7-B44A-FD9ED452EC6DQ34390050-D847A605-08B4-4456-B0F0-6DA0249BFB11Q34479105-A49DAA96-7ED0-42A9-8672-FB5845D59862Q35019665-F97FF5EA-00BD-4A8D-B972-B533155D00CDQ35032042-E3B6B6DF-3DCB-47E7-B430-FCE4A4DE44C2Q35033557-1F6D2273-2FF0-4907-822F-88DDE669C1AAQ35373683-F8869D31-BCBE-4034-B5F8-22685241E254Q36396620-9FF2CB53-4EBE-4867-9FAA-B5425B9F8086Q36709544-0A503D8D-AF3E-4B29-B06F-9B01E2A89511Q37326634-82FE6324-4F49-4C05-8A5F-1362F57A1455Q37378896-FCE40C09-B8C0-41F8-9304-AA133ADB50F1Q37380507-C362A5B2-71AF-430E-AEFA-D2AE78B527C7Q37387416-88831D66-B78E-440A-8E44-2695CB616BD3Q37486605-427E4E85-05C5-491A-BECA-ABA628377D71Q37550156-4786B7FB-B6BB-4888-AD98-9007976DC016Q37579228-86872B35-DE99-41A9-A76C-68781095A047Q37588694-21F0BFCE-6DC0-489F-9D6A-A862BB09F22BQ37629641-8C96E8AA-32EE-4405-AF49-8BDBE5D67CB9Q37693951-C3A6AB1C-0384-428F-B938-DFAA81E838F4Q37707419-557856A2-F229-4412-84C0-E412897B578FQ37716022-FEB67813-16A7-40B9-A8B9-52ECBC367039Q37744524-9A8B90A8-3813-448F-8FEE-D10B0052E7D0Q37749813-48577058-3922-48E1-8F5F-626B1905DE83
P2860
Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Clopidogrel nonresponsiveness ...... atic review and meta-analysis.
@en
type
label
Clopidogrel nonresponsiveness ...... atic review and meta-analysis.
@en
prefLabel
Clopidogrel nonresponsiveness ...... atic review and meta-analysis.
@en
P2093
P50
P1476
Clopidogrel nonresponsiveness ...... matic review and meta-analysis
@en
P2093
J Wouter Jukema
Marcel M C Hovens
Menno V Huisman
P304
P356
10.1016/J.AHJ.2007.04.014
P407
P577
2007-08-01T00:00:00Z